Mechanism of Adenovirus E4-ORF3-Mediated SUMO Modifications

Sook-Young Sohn,a Patrick Hearinga

aDepartment of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, New York, USA

ABSTRACT Regulation of a variety of different cellular processes, including posttranslational modifications, is critical for the ability of many viruses to replicate efficiently within host cells. The adenovirus (Ad) E4-ORF3 protein assembles into polymers and forms a unique nuclear scaffold that leads to the relocalization and sequestration of cellular proteins, including small ubiquitin-like modifiers (SUMOs). Previously, we showed that E4-ORF3 functions as a SUMO E3 ligase of transcriptional intermediary factor-1 gamma (TIF-1γ) and promotes poly-SUMO chain formation. Here, we present cellular and biochemical data to further understand E4-ORF3 SUMO ligase activity. E4-ORF3 proteins from five different Ad species were found to possess SUMO E3 ligase activities in vitro. In infected cells, SUMO modifications of target proteins occurred only when the proteins were recruited into E4-ORF3 polymeric structures. By analyzing SUMO-deficient TIF-1γ, we demonstrated that SUMO conjugations are not required for E4-ORF3-mediated relocalization of target proteins in infected cells, implying that sequestration is followed by SUMO modification. In vitro SUMO conjugation assays revealed the Ad E1B-55K oncoprotein as a new viral target of E4-ORF3-mediated SUMOylation. We also verified a direct function of E4-ORF3 as a SUMO ligase for multiple cellular proteins, including transcription factor II-I (TFII-I), Nbs1, and Mre11. Moreover, we discovered that E4-ORF3 associates with SUMO-bound UBC9, and E4-ORF3 polymerization is crucial for this ternary interaction. Together, our findings characterize E4-ORF3 as a novel polymer-type SUMO E3 ligase and provide mechanistic insights into the role of E4-ORF3 in SUMO conjugation.

IMPORTANCE Viruses interplay with the host SUMOylation system to manipulate diverse cellular responses. The Ad E4-ORF3 protein forms a dynamic nuclear network to interfere with and exploit different host processes, including the DNA damage and interferon responses. We previously reported that E4-ORF3 is a SUMO E3 ligase. Here, we demonstrate that this activity is a conserved function of evolutionarily diverse human Ad E4-ORF3 proteins and that E4-ORF3 functions directly to promote SUMO conjugations to multiple cellular proteins. Recruitment of cellular substrates into E4-ORF3 nuclear inclusions is required for SUMO conjugation to occur in vivo. We probed the mechanism by which E4-ORF3 functions as a SUMO E3 ligase. Only multimeric, but not dimeric, E4-ORF3 binds to the SUMO E2 conjugation enzyme UBC9 in vitro only in a trimeric complex with SUMO. These results reveal a novel mechanism by which a conserved viral protein usurps the cellular SUMO conjugation machinery.

KEYWORDS adenoviruses, E3 ligase, E4-ORF3, SUMO, UBC9

The DNA tumor virus adenovirus (Ad) has evolved different mechanisms to target host cell processes to optimize the cellular environment during infection. Studies of the Ad replication cycle have revealed fundamental insights into the regulation of gene expression, protein translation, cell proliferation, and cell death (1). Studies of Ad infection have also provided unique insights into innate host responses to viral
infection, including the DNA damage response (DDR) and an interferon (IFN) response (2, 3). The linear double-stranded Ad genome is sensed in the cytoplasm to stimulate type I IFN production (2). Nuclear Ad DNA is sensed as double-strand breaks to trigger a DDR (3). The DDR and IFN responses significantly inhibit Ad replication if left unabated. Consequently, Ad has evolved multiple mechanisms to interfere with these innate immune pathways.

The Ad E4-ORF3 protein functions by relocalizing and sequestering cellular proteins into filamentous nuclear inclusions (4, 5). To prevent a DDR, E4-ORF3 sequesters Mre11, Rad50, and Nbs1 (the MRN complex) (6–8), which functions as a DNA damage sensor (9). With IFN signaling, E4-ORF3 relocalizes effectors of the pathway, including promyelocytic leukemia (PML) protein and PML nuclear body (PML-NB) components, including Sp100 and Daxx (4, 5, 10, 11). The E4-ORF3 protein also targets several transcription factors, including tripartite motif containing protein 24 (TRIM24)/transcriptional intermediary factor-1 alpha (TIF-1α), TRIM33/TIF-1γ, and transcription factor II-I (TFII-I) (1, 12–15). Ads are ubiquitous pathogens that infect a wide range of vertebrates. Nearly 90 human Ad types have been identified that are grouped into eight species (A to H). Interestingly, the E4-ORF3 proteins from different Ad species all target PML-NBs for disruption, but only species C Ad E4-ORF3 relocalizes MRN complex proteins (7).

Many cellular proteins that are relocalized by E4-ORF3 are modified by the small ubiquitin-like modifier (SUMO) (16, 17). SUMO modification regulates diverse cellular processes, including transcription, replication, DNA repair, protein localization, and protein stability, mostly by modulating protein-protein interactions (18, 19). SUMO conjugation to target lysine residues in substrates follows the paradigm of the ubiquitin conjugation system (18, 19). The C-terminal diglycine motif of a processed SUMO is conjugated to a catalytic cysteine residue of the E1-activating enzyme. SUMO is then transferred to the catalytic cysteine of the E2-conjugating enzyme. In humans, there is one heterodimeric SUMO E1-activating enzyme (SAE1/SAE2) and one E2-conjugating enzyme (UBC9). SUMO may be directly transferred from the E2 enzyme to a substrate or the activity of an E3 ligase may promote the process. Only a limited number of SUMO E3 ligases have been identified, and much less is known about them compared with ubiquitin E3 ligases. In humans, three SUMO paralogs, SUMO-1, -2, and -3 are best characterized in this family (18, 19). Mature SUMO-2 and SUMO-3 proteins are 97% identical and often referred to as SUMO-2/3. The SUMO-1 protein is ~50% identical to SUMO-2/3. SUMO-2/3, but not SUMO-1, can form polymeric SUMO chains via conjugation at SUMO-2/3 lysine residue 11.

We previously demonstrated that the Ad5 E4-ORF3 protein promotes SUMO modifications of multiple cellular proteins and further targets some of them for ubiquitin-dependent proteasomal degradation (1, 12, 16, 17, 20). Using in vitro SUMOylation assays, we showed that the Ad5 E4-ORF3 protein itself functions as a SUMO E3 ligase (20). These findings place the Ad E4-ORF3 protein at the nexus of the cellular SUMOylation system. A growing number of studies have demonstrated that viruses manipulate host SUMOylation pathways (21). Interestingly, it was found that disruption of global SUMO modification in immune cells results in enhanced type I IFN responses (22, 23). This result suggests that SUMOylation plays important roles in aspects of antiviral activity as well as virus replication.

In this report, we further characterized E4-ORF3-mediated SUMOylation by analyzing E4-ORF3 proteins from evolutionarily diverse human Ads and if divergent E4-ORF3 target proteins are regulated by distinct mechanisms. Our results demonstrate that in vitro SUMO ligase activity is conserved across human Ad types, and that recruitment of cellular proteins into E4-ORF3 nuclear inclusions is required for their SUMOylation in infected cells. Using in vitro binding assays, we reveal a novel mechanism by which the E4-ORF3 protein interacts with E2 UBC9 and SUMO-3 via formation of a trimeric protein complex. Overall, these results provide mechanistic insights into the activity of a conserved viral protein whose function impacts multiple nuclear signaling pathways by a unique mechanism.
RESULTS

Ad E4-ORF3-mediated TIF-1γ subnuclear relocalization and E4-ORF3 SUMO E3 ligase activities are conserved among human Ad types. Ad E4-ORF3 target proteins can be divided into two groups based on their altered subnuclear localization mediated by different human Ad types. One group of targets, such as Mre11, Nbs1, Rad50, and TFII-I, are sequestered by E4-ORF3 from only species C Ads, such as Ad2 and Ad5 (7, 12, 17). On the other hand, PML, TIF-1α, and SUMO-1, -2, and -3 are recruited into nuclear inclusions formed by E4-ORF3 from all types of Ads examined (7, 14, 17). E4-ORF3 proteins from Ad5 and Ad12 relocalize TIF-1γ into nuclear inclusions (13, 15, 20). We determined the effect of E4-ORF3 from Ad species A to E on TIF-1γ localization by immunofluorescence. HeLa cells were infected with recombinant Ads expressing hemagglutinin (HA)-tagged E4-ORF3 proteins from Ad12, 3, 5, 9, and 4 belonging to species A, B, C, D, and E, respectively. Since E4-ORF3 induces proteasomal degradation of TIF-1γ (15, 20), we examined TIF-1γ localization in Ad-infected cells before a major loss of protein takes place (8 hours postinfection [hpi]). As seen in Fig. 1A, TIF-1γ was relocalized by the E4-ORF3 proteins from all five different species.

Our previous study revealed that Ad5 E4-ORF3 functions as a SUMO E3 ligase for TIF-1γ using an in vitro SUMOylation reaction (20). We also showed that Ad5 E4-ORF3 promotes poly-SUMO-3 chain formation in the absence of substrate. Phylogenetic relationships of the E4-ORF3 proteins of different Ad types are shown in Fig. 1B. The Ad5 E4-ORF3 protein has diverged significantly from those of other Ad species. Therefore, we investigated whether this SUMO E3 ligase activity of E4-ORF3 is conserved among the Ad types. In cultured cells, all the E4-ORF3 proteins tested were able to enhance SUMO-3 conjugation to TIF-1γ and promote TIF-1γ degradation (Fig. 1C, pulldown and lysate, respectively). We next analyzed SUMO E3 ligase activities using an in vitro SUMO conjugation assay. Recombinant E4-ORF3 proteins were purified from Escherichia coli and their ligase activities determined in the absence or presence of a substrate, glutathione S-transferase (GST)-tagged TIF-1γΔCT (20). As described in our previous report (20), we optimized the reaction conditions such that weak TIF-1γ SUMOylation was evident with E2 alone. We then incubated reaction mixtures with increasing concentrations of E4-ORF3 proteins. Consistent with the observation in Fig. 1B, the E4-ORF3 proteins of all different Ad types facilitated SUMO-3 conjugation to TIF-1γ (Fig. 1D, as well as poly-SUMO-3 chain formation (Fig. 1E). The Ad5 E4-ORF3 L103A mutant, which is defective in the formation of polymeric nuclear tracks and subsequent E4-ORF3 functions (6), was used as a negative control. Taken together, our data indicate that SUMO E3 ligase activities of E4-ORF3 for TIF-1γ SUMOylation and poly-SUMO chain formation are conserved across human Ad species.

E4-ORF3 enhances SUMO-1 and SUMO-3 conjugation to TIF-1γ and TFII-I. We previously found that Ad5 E4-ORF3 induces SUMO conjugation to TFII-I in cultured cells (12, 16). To determine whether E4-ORF3 directly functions as a SUMO E3 ligase for TFII-I, as it does to TIF-1γ, TFII-I protein was purified from E. coli (GST-TFII-I) and analyzed as a substrate in vitro for SUMO-3 conjugation in the absence or presence of E4-ORF3. Similar to TIF-1γ (Fig. 2A, bottom), TFII-I was modified by SUMO-3 with E2 alone, and this modification was significantly enhanced by incubation with Ad5 E4-ORF3 (Fig. 2B, bottom, – versus + E4-ORF3). This result demonstrates that Ad5 E4-ORF3 directly acts as a SUMO E3 ligase for TFII-I. In cultured cells, E4-ORF3 induces both SUMO-1 and SUMO-3 modification of TFII-I (12). Thus, we sought to determine whether E4-ORF3 itself can induce SUMO-1 conjugation to TIF-1γ and TFII-I in vitro. Interestingly, E4-ORF3 exhibited E3 ligase activity for SUMO-1 conjugation to these substrates (Fig. 2A and B, top).

TFII-I subnuclear relocalization and SUMOylation are induced by E4-ORF3 from only species C (Ad5) but not by any other Ad types in cultured cells (12). Because E4-ORF3 proteins from five different types showed E3 ligase activities for TIF-1γ SUMOylation and poly-SUMO-3 chain formation (Fig. 1D and E), we asked whether the ligase activity of E4-ORF3 for TFII-I SUMOylation is specific for Ad5 in vitro. We performed an in vitro SUMOylation assay of TFII-I using E4-ORF3 proteins from five types and compared
SUMOylation levels. All of the E4-ORF3 proteins were able to promote SUMO-3 conjugation to TFII-I in vitro (Fig. 2C), indicating that E4-ORF3 proteins from different Ad types possess E3 ligase activities for TFII-I SUMOylation. These results imply that the defect in induction of TFII-I SUMOylation displayed by E4-ORF3 proteins from Ad types other than species C in vivo is mainly caused by a lack of their ability to relocalize TFII-I into E4-ORF3 nuclear inclusions, not by a lack of E4-ORF3 SUMO E3 ligase activities.
Ad5 E4-ORF3 functions as a SUMO E3 ligase for Nbs1, Mre11, and Ad5 E1B-55K.

Since we found multiple cellular proteins that are targeted for E4-ORF3-mediated SUMOylation, we asked if E4-ORF3 affects SUMOylation of other Ad viral proteins. Ad5 E1B-55K oncoprotein is a well-known SUMO substrate, and SUMO-1 modification at the lysine 104 residue is required for the transforming activity of E1B-55K (24, 25). In agreement with previous reports (26, 27), E1B-55K was recruited into E4-ORF3 tracks in HeLa cells infected with an E4-ORF6-deficient Ad5 mutant virus (dl355), while it colocalized with viral replication centers in the absence of E4-ORF3 and E4-ORF6 (dl355-inORF3) at 12 hpi (Fig. 3A). Next, to determine SUMOylation levels of E1B-55K, His6-tagged SUMO-expressing HeLa cells were infected with titers indicated in Fig. 3 to obtain similar levels of viral protein expression. Consistent with previous reports, E1B-55K was modified by both SUMO-1 and SUMO-3 in Ad5-infected cells (Fig. 3B). Surprisingly, only SUMO-1, but not SUMO-3, conjugation to E1B-55K was significantly increased by E4-ORF3 (Fig. 3B), indicating that E4-ORF3 enhances SUMO-1 conjugation to E1B-55K in the absence of E4-ORF6.

To further investigate the effect of E4-ORF3 on E1B-55K SUMOylation using an in vitro assay, Ad5 E1B-55K was purified from E. coli (GST-E1B-55K). Using the in vitro SUMO reaction, a single SUMO-1-conjugated Ad5 E1B-55K was observed, consistent with previous reports (24, 25). Interestingly, this SUMO-1 modification was enhanced by incubation with Ad5 E4-ORF3 (Fig. 3C), even though the increase in SUMOylation by E4-ORF3 was less than that observed with TIF-1γ and TFII-I (Fig. 2). Collectively, these data suggest that E4-ORF3 enhances SUMO-1 conjugation to E1B-55K by E4-ORF3 E3 ligase activity as well as recruitment of E1B-55K to its nuclear inclusions. These results
provide the first direct evidence that E4-ORF3 functions as a SUMO E3 ligase for a viral protein as well as cellular proteins.

Next, we determined if E4-ORF3 directly functions as a SUMO E3 ligase for Nbs1 and Mre11, which were the first identified SUMO targets affected by E4-ORF3 in cultured cells (17). Nbs1 and Mre11 were purified from *E. coli* (GST-Nbs1 and GST-Mre11) and their SUMOylation levels assessed by incubating with Ad5 E4-ORF3 in *in vitro* reactions. SUMO-1 and SUMO-3 conjugation to Nbs1 occurred weakly in the absence of E4-ORF3, but the modifications were significantly increased by E4-ORF3 (Fig. 3D, top). In the case of Mre11, no SUMO-modified Mre11 was detected in the absence of E4-ORF3, but weak SUMO-1 modification and pronounced SUMO-3 modification were observed in the presence of E4-ORF3 (Fig. 3D, bottom). These results demonstrate that Ad5 E4-ORF3 indeed functions as a SUMO E3 ligase of Mre11 and Nbs1. Although Ad5 E4-ORF3 still exhibited E3 ligase activity on all of the substrates examined, E4-ORF3-induced SUMOylation of Mre11, Nbs1, and E1B-55K was much weaker than that of TIF-1γ and TFII-I. All of these substrates were purified under the same native (nondenaturing) conditions, implying the possible involvement of cellular factors for SUMOylation *in vivo*.

**E4-ORF3-mediated relocalization of TIF-1γ into nuclear inclusions does not require SUMO conjugation.** In our previous study, suppression of global SUMO conjugations by expressing SUMO-specific protease (SENP) 1 did not affect sequestration of Mre11 and Nbs1 into E4-ORF3 nuclear inclusions (17), suggesting that SUMOylation of E4-ORF3 target proteins may not be required for relocalization to occur. Since SUMOylation sites of TIF-1γ have been identified at lysines 776, 793, 796, and 839 (28), we examined the effect of TIF-1γ SUMOylation on subcellular relocalization by E4-ORF3 using this SUMO-deficient mutant, 4KR (28). Full-length TIF-1γ wild-type and 4KR were purified from *E. coli* (GST-TIF-1γ-WT and -4KR), and an
in vitro SUMOylation assay was performed. As expected, the TIF-1γ 4KR mutations resulted in a complete failure of SUMOylation in the absence or presence of Ad5 E4-ORF (Fig. 4A). Next, human bronchial epithelial cells (HBEC-3KT) were cotransfected with an HA-E4-ORF3 expression vector and empty, FLAG-TIF-1/H9253-WT, or -4KR expression plasmids and TIF-1γ subcellular localization determined by immunofluorescence. Consistent with previous reports, both endogenous and transiently expressed TIF-1γ were relocated by E4-ORF3 (Fig. 4B, E.V. and WT, respectively). TIF-1γ relocalization was observed in all cells that expressed E4-ORF3. Interestingly, the SUMOylation-defective TIF-1γ-4KR mutant was also relocated into E4-ORF3 nuclear inclusions (Fig. 4B, 4KR). These results provide compelling evidence that E4-ORF3-mediated relocalization of cellular proteins into nuclear inclusions is independent of their SUMO modification status.

**E4-ORF3 interacts with UBC9 in the presence of SUMO-3.** We showed binding of Ad5 E4-ORF3 with UBC9 in cultured cells by coimmunoprecipitation (20). To assess whether this binding is direct or requires other factors, GST pulldown analyses were carried out using recombinant proteins, GST and GST-UBC9, and His6-tagged proteins E4-ORF3-WT, -L103A, and -N82A. Point mutations at the highly conserved L103 or N82 residues in E4-ORF3 still allow the formation of an E4-ORF3 dimer but completely block polymer assembly (29, 30). Surprisingly, Ad5 E4-ORF3 was not coprecipitated with UBC9 alone (Fig. 5A), indicating that they are not directly associated each other. Strikingly, the addition of SUMO-3 to the binding mixture enabled efficient E4-ORF3-WT pulldown with UBC9 (Fig. 5A). In contrast, the L103A and N82A mutant proteins were completely defective in this binding (Fig. 5A), suggesting that E4-ORF3 polymerization is crucial for this interaction to occur.
In our previous study, we demonstrated that mutations in the predicted SUMO-interacting motif (SIM) of E4-ORF3 (amino acids 103 to 106) did not affect E4-ORF3-mediated TIF-1γ SUMOylation (20). To further test the interaction between E4-ORF3 and SUMO-3, we incubated His$_{6}$-E4-ORF3-WT and L103A and N82A mutant proteins, with either GST-SUMO-3 or untagged SUMO-3, followed by pulldown with glutathione agarose or nickel ion-nitrilotriacetic acid (Ni$^{2+}$-NTA) agarose beads (Fig. 5D and E). There was no detectable coprecipitation of E4-ORF3 and SUMO-3 with either approach, indicating that E4-ORF3 does not bind SUMO-3 alone. These results establish that UBC9, SUMO-3, and E4-ORF3 proteins form a stable ternary complex.

Since E4-ORF3 proteins from five different Ad types were found to possess SUMO E3 ligase activities, we next questioned whether the ternary interactions of E4-ORF3,
SUMO-3, and UBC9 are conserved among Ad types. We confirmed that E4-ORF3 proteins from Ad 12, 3, 9, and 4 all bound SUMO-3/UBC9 (Fig. 5C), demonstrating that the ability of E4-ORF3 to form ternary interactions with SUMO and UBC9 is conserved across Ad species.

Previous reports have shown that E4-ORF3 recruits SUMO-1 and -2/3 into the nuclear inclusions (7, 17). To determine the subcellular localization of UBC9 in the presence of E4-ORF3, E4-ORF3 was expressed in HeLa cells, and endogenous UBC9 localization was analyzed by high-resolution microscopy. UBC9 mostly localized within the nucleus in a diffuse pattern, and E4-ORF3 expression did not make significant changes in this localization. However, colocalization of UBC9 and E4-ORF3 was observed at multiple sites throughout the nucleus in all cells that expressed E4-ORF3 (Fig. 5B).

E4-ORF3 associates with backside SUMO-bound UBC9. We sought to understand the mechanism of how E4-ORF3 associates with UBC9 together with SUMO-3. The C-terminal glycine of SUMO forms a thioester linkage via the catalytic cysteine of UBC9. A second SUMO moiety may bind noncovalently on the backside of UBC9 that is opposite to the active-site cysteine 93 residue (31). For the backside binding interaction, the interfaces are found to be formed by basic amino acids in UBC9 (R13, R17, and H20) and acidic amino acids in SUMO (E67 in SUMO-1, D63 in SUMO-2, and D62 in SUMO-3) (32). Since the GST pulldown assays were conducted under conditions without E1 and ATP, SUMO conjugation to the catalytic cysteine of UBC9 did not occur, suggesting the possibility of a requirement for noncovalent binding between SUMO-3 and UBC9 for interaction with E4-ORF3. To test this possibility, the UBC9 backside-binding-deficient SUMO-3-D62R mutant was purified from E. coli, and GST pulldown assays were conducted as described above. Remarkably, E4-ORF3 was not able to interact with UBC9 in the presence of SUMO-3-D62R instead of SUMO-3-WT (Fig. 6A), indicating that backside binding by SUMO-3 to UBC9 is essential for the ternary interaction with Ad5 E4-ORF3. To examine the correlation between the E4-ORF3 SUMO E3 ligase activity and ternary interactions, in vitro poly-SUMOylation assays were carried out using the SUMO-3-WT, SUMO-3-D62R mutant, and polymerization-defective SUMO-3-K11R mutant in the presence of Ad5 E4-ORF3 in the absence of substrate. As expected, the SUMO-3-K11R polymerization mutant showed no SUMO conjugation. Poly-SUMOylation of the SUMO-3-D62R mutant occurred poorly in the absence of E4-ORF3, and the addition of increasing amounts of E4-ORF3 exhibited only weak changes in D62R chain formation compared to wild-type SUMO-3 (Fig. 6B). These results support the conclusion that backside binding of SUMO-3 to UBC9 is required for enhanced poly-SUMO chain formation by E4-ORF3.

SUMO-1 and SUMO-2 are found to bind UBC9 with similar affinities, although UBC9 backside binding by SUMO-2/3 is implicated in poly-SUMO chain formation (31). We asked whether E4-ORF3 has any SUMO paralog preference for the ternary interaction with UBC9 by comparing pulldown with SUMO-1 and SUMO-3. Importantly, Ad5 E4-ORF3 exhibited a very weak interaction with SUMO-1/UBC9 compared to SUMO-3/UBC9 (Fig. 6C), demonstrating that E4-ORF3 preferentially binds to SUMO-3/UBC9 over SUMO-1/UBC9.

DISCUSSION

SUMO E3 ligases increase the rate of SUMO transfer from the E2-conjugating enzyme UBC9 to substrates by recruiting SUMO-charged UBC9 and substrates into a complex and stabilizing SUMO-charged UBC9 in an activated closed conformation (18, 19). The activities of known cellular SUMO E3 ligases fall into two categories. Members of the Siz/PIAS family of SUMO E3 ligases contain a RING domain which interacts with SUMO-charged UBC9. Siz/PIAS proteins are thought to function in an analogous manner to RING-type ubiquitin E3 ligases and function as adaptors to promote SUMO-UBC9 and substrate interaction to facilitate conjugation. RANBP2 and ZNF451 are SUMO E3 ligases that lack a RING domain. These proteins bind SUMO and SUMO-charged UBC9 and promote SUMO conjugation by serving as adaptor proteins between
substrates and SUMOylation components. In this study, we investigated how the Ad E4-ORF3 protein functions as a SUMO E3 ligase and define parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.

The Ad E4-ORF3 protein functions as a SUMO E3 ligase and defines parameters associated with substrate specificity.

The Ad5 E4-ORF3 protein has been shown to relocalize SUMO and SUMOylated substrates into nuclear inclusions to facilitate SUMO conjugation in infected cells (17). The structure of the E4-ORF3 protein has been solved (30), and E4-ORF3 does not have a RING domain. E4-ORF3 residues 103 to 107 are a predicted SIM, but these sequences are not critical for E4-ORF3 SUMO ligase activity (20). Here, we showed that the E4-ORF3 protein does not directly bind either SUMO or UBC9 alone. Instead, E4-ORF3 binds UBC9 only in a trimeric complex with backside-bound SUMO (Fig. 5 and 6). Charging of UBC9 via thioester linkage of SUMO to the catalytic cysteine residue is not required for these interactions to occur. Furthermore, our results using E4-ORF3 N82A and L103A mutants revealed that E4-ORF3 polymerization is crucial for this interaction. Based on these results, we propose a model for a trimeric interaction of E4-ORF3 with UBC9 and backside-bound SUMO.
emerged interface created by UBC9 and backside-bound SUMO. We hypothesize that E4-ORF3 functions to recruit the SUMO machinery, including UBC9 (Fig. 5B), and its substrates in proximity of one another using its polyvalent scaffold (29, 30) to assemble higher-order protein complexes.

To elucidate the characteristics of E4-ORF3-mediated SUMO conjugation and conservation of function, we analyzed E4-ORF3 proteins from different Ad species and divergent substrate proteins. The in vitro E3 ligase activity of Ad5 E4-ORF3 was conserved across the Ad types tested (species A to E) (Fig. 1), even though Ad5 E4-ORF3 shares only 50% or less amino acid sequence identity with E4-ORF3 of other Ad types. In infected cells, SUMO conjugation to proteins occurred only when substrates were recruited into E4-ORF3 nuclear inclusions generated by each Ad type (12, 16, 17, 20). Why the E4-ORF3 proteins of different Ad species differ in their abilities to relocalize certain cellular proteins such as Nbs1, Mre11, and TFII-I (7, 12) is not understood structurally or functionally. We previously suggested that relocalization of cellular proteins by E4-ORF3 is a prerequisite for their SUMOylation (17).

Since the SUMOylation-deficient TIF-1γ protein was efficiently recruited into E4-ORF3 inclusions (Fig. 4), SUMOylation of target proteins is not a requirement for E4-ORF3-mediated relocalization, confirming that relocalization is followed by SUMO conjugation. Collectively, our data demonstrate that both E4-ORF3 polymerization, which is essential for its in vitro SUMO E3 ligase activity, and substrate recruitment into the nuclear scaffold are required for E4-ORF3-mediated SUMOylation in infected cells.

We previously reported that E4-ORF3 promotes SUMO-2 or SUMO-3 conjugation to substrates with a higher efficiency than SUMO-1 in infected cells with Nbs1, Mre11, and, to a lesser extent, TFII-I (12, 17). Here, we found that E4-ORF3 preferentially formed a ternary interaction with SUMO-3/UBC9 compared to SUMO-1/UBC9 (Fig. 6), consistent with these results. A greater extent of SUMO-3, compared to SUMO-1, conjugation to these substrates was recapitulated in vitro (Fig. 2 and 3), indicating that preferential binding of E4-ORF3 to SUMO-3/UBC9 may represent the basis for these results. We also observed E4-ORF3-mediated SUMO-1 conjugation to the Ad5 E1B-55K protein in vitro and enhancement of E1B-55K SUMO-1, but not SUMO-3, conjugation by E4-ORF3 in infected cells (Fig. 3). This is the first demonstration of the involvement of the E4-ORF3 protein in the regulation of E1B-55K SUMOylation, a process that is critical for certain activities of this protein (24, 25). Interestingly, E4-ORF3 cooperates with the Ad E1A and E1B proteins to transform rodent cells, and the E4-ORF3 protein was found to interact with E1B-55K (35). Since SUMO-1 modification of E1B-55K is required for its transformation properties (24), it seems likely that the role of E4-ORF3 in transformation may be to function as a SUMO E3 ligase and promote E1B-55K SUMOylation.

As we and others previously reported (12, 15, 20), E4-ORF3-mediated SUMOylation results in proteasomal degradation of TFII-I and TIF-1γ but not Mre11 and Nbs1. The basis for this discrimination in the outcome of E4-ORF3-induced SUMOylation of cellular substrates in not clear at this time. In this study, we confirmed that E4-ORF3 functions as a SUMO E3 ligase of Mre11 and Nbs1, although in vitro SUMOylation levels of Mre11 and Nbs1 were much lower than those of TIF-1γ and TFII-I, implying a possibility for the involvement of cellular factors. The types of SUMO modification that occur with different substrates targeted by E4-ORF3, e.g., mono- versus poly-SUMOylation, may explain the different outcomes of the process. A wide range of different DNA and RNA viruses impact host protein SUMOylation (36). However, only a few viral proteins have been described as SUMO E3 ligases. Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase, K-bZIP, that is SIM dependent and specific for SUMO-2/3 modification (37). The Ad E1B-55K protein is a SUMO E3 ligase that is SIM-1 specific (38). E1B-55K regulates SUMOylation by an unknown mechanism. The Ad E4-ORF3 protein functions as a SUMO E3 ligase by an entirely novel mechanism. It binds a backside-bound SUMO-UBC9 complex and tethers this complex with a number of different cellular substrates through higher-order protein-protein interactions. E4-ORF3 directs both SUMO-1 and SUMO-2/3 conjugation and regulates cellular proteins involved in a range of functions, including IFN signaling, the DDR, and transcriptional regulation.
MATERIALS AND METHODS

Cells, viruses, and transfection. The human bronchial epithelial cell (HBEC) 3-KT (American Type Culture Collection [ATCC]) was cultured in airway epithelial cell basal medium (ATCC) supplemented with the bronchial epithelial cell growth kit (ATCC) and maintained according to the provider’s instructions. HeLa cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (vol/vol) calf serum and 1% (vol/vol) penicillin-streptomycin. The stable expressing His6-tagged SUMO-1 and His6-tagged SUMO-3 were generously provided by Ronald Hay (University of Dundee); these cells were selected to express His6-tagged SUMO proteins at levels comparable to endogenous SUMO proteins (39). For transfection, Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) was used for HBE3-KT cells, and polyethyl- enamine (PEI; Polysciences) was used for HeLa cells. The viruses used in this study include wild-type Ad5, d35S-ΔE4-ORF6, and d35S-ΔnORF3 (ΔE4-ORF3/ΔE4-ORF6) (40). The E1 replacement viruses that express HA-tagged E4-ORF3 of Ad3, 4, 5, 9, and 12 under the control of a cytomembranavirus (CMV) promoter were previously described (6, 41). Viral preparation and infection were performed as described previously (6).

Plasmids and recombinant proteins. The HA-tagged E4-ORF3 expression vector was described previously (17). FLAG-tagged TIF-1γ and SUMO-deficient mutant 4KR (K776R, K793R, K796R, and K839R) (28) expression plasmids were provided by Rta Rimokh (Université de Lyon). Recombinant human SUMO E1 and E2 enzymes and untagged SUMO-3 were purchased from Boston Biochem. The rest of the recombinant proteins used in this study were expressed in Rosetta E. coli cells and purified using either Ni2⁺-NTA agarose (Qagen) or glutathione agarose (Sigma-Aldrich), as previously described (20, 29). The E4-ORF3 coding regions of human Ad3, 4, 5, 9, 12, and AdS E4-ORF3 mutants, the L103A and N82A mutants, were inserted into the bacterial expression plasmid pProEx HTb. GST-tagged TIF-1γΔCT (20) and 4KR were cloned in pGEX-4T-1, GST-tagged Nbs1 was cloned in pGEX-3X, and GST-tagged TFIIF-I and Mre11 were cloned in pGEX-KG. Based on advice from David A. Ornelles (Wake Forest University) about unwanted recombination between the E1B-55K coding region and E. coli chromosome DNA, we generated an E1B-55K expression plasmid containing scrambled synonymous codons while maintaining the wild-type protein sequence and optimized for protein expression in E. coli (42). The altered Ad5 E1B-55K coding sequence was kindly designed by Justin Gardin (Stony Brook University). The optimized E1B-55K coding region was synthesized from Biomatik and cloned in pGEX-KG. The GST-Ubc9 expression plasmid pGEX-3X-Ubc9 was provided by Stephen Goff (Columbia University). SUMO-1 and SUMO-3 coding regions were cloned in pET28a. SUMO-3-D62R and SUMO-3-K11R mutants were generated by site-directed mutagenesis.

Antibodies. The anti-TIF-1γ rabbit antibody was generated as previously described (13). The anti-E4-ORF3 rat monoclonal antibody (6A-11) was provided by Thomas Dobner (Heinrich-Pette Institute), the anti-E1B-55K (2A6) mouse monoclonal antibody was from Arnold Levine (Princeton University), and the rabbit polyclonal anti-DBP antibody was from Peter van der Vliet (University of Utrecht). The mouse anti-RanGAP1, rabbit anti-HA, and rabbit anti-SUMO-1 antibody was from Cell Signaling Technology, and the anti-Ubc9 rabbit polyclonal antibodies were from Santa Cruz Biotechnology. The anti-Mre11 and anti-Nbs1 mouse monoclonal antibodies were from GenTex. The rabbit anti-SUMO-1 antibody was from Cell Signaling Technology, and the anti-Ubc9 rabbit polyclonal antibodies were from Cell Signaling Technology and Proteintech. The anti-SUMO-2/3 rabbit polyclonal antibody was from Thermo Fisher Scientific, the anti-His mouse monoclonal antibody was from Clontech, and the anti-HA rabbit polyclonal antibody was from Rockland.

In vivo SUMOylation assay. The parent HeLa or His6-tagged SUMO-1- and SUMO-3-expressing HeLa cells were infected with viruses indicated in the text, and SUMO conjugates were captured and analyzed as described by Tatham et al. (39).

In vitro SUMOylation assay. SUMO conjugation reactions were performed using 100 nM substrate protein, 50 μM SUMO, 20 to 50 nM E1, 150 to 250 nM E2, and 0.1 to 9 μM E4-ORF3 in a SUMOylation reaction buffer (20 mM HEPES [pH 7.5], 0.5 mM EGTA, 1 mM dithiothreitol [DTT], 0.5% Tween 20, 2 mM ATP, and 5 mM MgCl2) at 37°C for the indicated time periods. Poly-SUMO-3 chain assembly reactions were performed as described above minus substrate protein.

GST pulldown. The following amounts of recombinant proteins were used for pulldown assays: 0.1 nM GST, 0.1 nM GST-Ubc9, 0.25 nM His6-E4-ORF3, and 0.4 nM His6-SUMO. His6-E4-ORF3 and His6-SUMO proteins in binding buffer (10 mM Tris [pH 8.0], 2.5 mM β-mercaptoethanol, and 0.1% Triton X-100) were precleared by incubating with glutathione agarose beads at 4°C for 30 min. GST and GST-Ubc9 proteins were incubated with glutathione agarose beads at 4°C for 60 min in binding buffer. Precleared E4-ORF3 and SUMO proteins were added into the binding mix and incubated for an additional 3 h. The beads were washed five times with wash buffer (10 mM Tris [pH 8.0], 2.5 mM β-mercaptoethanol, and 0.5% Triton X-100). Bead-bound proteins were eluted in 2× Laemmli sample buffer and analyzed by Western blotting.

Immunofluorescence assay and microscopy. Cells were fixed with 4% (vol/vol) formaldehyde and permeabilized with 0.5% Triton X-100. After blocking in 10% goat serum, HA-tagged E4-ORF3 from Ad3, 4, 5, 9, and 12, and endogenous TIF-1γ were detected with anti-HA and anti-TIF-1γ antibodies, respectively. Cell images were acquired on an Axiovert 200M digital deconvolution microscope (Zeiss) and analyzed using the AxioVision software. Subcellular localization of TIF-1γ wild-type and SUMO-deficient 4KR, E1B-55K, and endogenous Ubc9 was determined by structured illumination microscopy (N-SIM; Nikon), and images were reconstructed and analyzed using the NIS-Elements software (Nikon).

ACKNOWLEDGMENTS

We are grateful to Ronald Hay (University of Dundee) for providing His6-SUMO cell lines. We thank Thomas Dobner (Heinrich-Pette Institute) for the anti-E4-ORF3 rat
monoclonal antibody, Arnold Levine (Princeton University) for the anti-DBP mouse monoclonal antibodies, and Peter van der Veit (University Utrecht) for the anti-DBP rabbit antibody. We thank Ruth Rimokh (University Lyon) for the SUMOylation-deficient TIF-1γ mutant construct. We are very grateful to David Omelchuk (Wake Forest University) for advice regarding the E1B protein expression vector in E. coli and Justin Gardin (Stony Brook University) for designing the reconfigured E1B vector. We thank Guo-Wei Tien (Stony Brook University) for help with the high-resolution microscopy and members of our laboratory for informed discussions. We thank Aniska Chikhalya for critical review of the manuscript.

This work was supported by NIH grant CA122677 to P.H.

The funding agency had no role in the design of the study, data collection or interpretation, or the decision to submit the work for publication. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

S.-Y.S. and P.H. designed the experiments. S.-Y.S. executed the experiments. S.-Y.S. and P.H. analyzed the data. S.-Y.S. and P.H. prepared the manuscript.

REFERENCES

1. Berk A. 2013. Adenoviridae, p 1704–1731. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. 2014. Innate immunity to adenovirus. Hum Gene Ther 25:265–284. https://doi.org/10.1089/hum.2014.001.
3. Weitzman MD, Weitzman JB. 2014. What’s the damage? The impact of noncanonical type I interferon response. Proc Natl Acad Sci USA 111:6725–6730. https://doi.org/10.1073/pnas.1603872113.
4. Everett RD, Boutell C, Hale BG. 2013. Interplay between viruses and host SUMOylation pathways. Nat Rev Microbiol 11:400–411.
5. Crowl JT, Stetson DB. 2018. SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response. Proc Natl Acad Sci U S A 115:6798–6803. https://doi.org/10.1073/pnas.1802114115.
6. Endter C, Kzhyshkowska J, Stauber R, Dobner T. 2001. SUMO-1 modification is required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc Natl Acad Sci USA 98:11312–11317. doi.org/10.1073/pnas.191361798.
7. Knudsmüller K, Groitzl P, Kiril B, Blancheotte P, Hauber J, Dobner T. 2007. Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation. J Virol 81:6684–6689. https://doi.org/10.1128/JVI.00723-08.
8. Vink EL, Yondola MA, Wu K, Hearing P. 2012. Adenovirus E4-ORF3-dependent relocalization of TIF-1γ and TIF-1γ relies on access to the coiled-coil motif. Virol 422:317–325. https://doi.org/10.1016/j.virol.2011.01.033.
9. Yondola MA, Hearing P. 2007. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol 81:4264–4271. https://doi.org/10.1128/JVI.02629-06.
10. Forrestor NA, Patel RN, Spieseder T, Groitzl P, Sedgwigg GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS, Dobner T, Grand RA, Martin A, Turner AS. 2012. Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection. J Virol 86:3167–3179. https://doi.org/10.1128/JVI.06583-11.
11. Sohn S-Y, Bridges RG, Hearing P. 2015. Proteomic analysis of ubiquitin-like posttranslational modifications induced by the adenovirus E4-ORF3 protein. J Virol 89:1744–1755. https://doi.org/10.1128/JVI.02892-14.
12. Sohn S-Y, Hearing P. 2012. Adenovirus regulates sumoylation of Mre11-Rad50-Nbs1 components through a paralog-specific mechanism. J Virol 86:9656–9665. https://doi.org/10.1128/JVI.01273-12.
13. Pichler A, Fatouros C, Lee H, Eisenhardt N. 2017. SUMO conjugation—a mechanistic view. Biomol Concepts 8:13–36. https://doi.org/10.1515/bmc-2016-0030.
14. Sohn S-Y, Hearing P. 2016. The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1γ SUMOylation and poly-SUMO chain elongation. Proc Natl Acad Sci U S A 113:6725–6730. https://doi.org/10.1073/pnas.1603872113.
15. Decque A, Joffre O, Malgaheas JG, Cossec JC, Blecher-Gonen R, Lapaque tette P, Silvin A, Manel N, Joubert PE, Seeler JS, Albert ML, Ami Gorena S, De Jean A. 2016. SUMOylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. Nat Immunol 17:140–149. https://doi.org/10.1038/ni.3342.
16. Endter C, Kzhyshkowska J, Stobaer R, Dobner T. 2001. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc Natl Acad Sci U S A 98:11312–11317. https://doi.org/10.1073/pnas.191361798.
17. Hesling C, Rimokh R. 2013. TIF-1δ SUMOylation and poly-SUMO chain elongation. Proc Natl Acad Sci U S A 110:6664–6673. https://doi.org/10.1073/pnas.1306118110.
18. Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. 2014. Innate immunity to adenovirus. Hum Gene Ther 25:265–284. https://doi.org/10.1089/hum.2014.001.
19. Pichler A, Fatouros C, Lee H, Eisenhardt N. 2017. SUMO conjugation—a mechanistic view. Biomol Concepts 8:13–36. https://doi.org/10.1515/bmc-2016-0030.
20. Sohn S-Y, Hearing P. 2016. The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1γ SUMOylation and poly-SUMO chain elongation. Proc Natl Acad Sci U S A 113:6725–6730. https://doi.org/10.1073/pnas.1603872113.
21. Everett RD, Boutell C, Hale BG. 2013. Interplay between viruses and host SUMOylation pathways. Nat Rev Microbiol 11:400–411. https://doi.org/10.1038/nrmicro3015.
22. Decque A, Joffre O, Malgaheas JG, Cossec JC, Blecher-Gonen R, Lapaque tette P, Silvin A, Manel N, Joubert PE, Seeler JS, Albert ML, Ami Gorena S, De Jean A. 2016. SUMOylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. Nat Immunol 17:140–149. https://doi.org/10.1038/ni.3342.
23. Endter C, Kzhyshkowska J, Stobaer R, Dobner T. 2001. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc Natl Acad Sci U S A 98:11312–11317. https://doi.org/10.1073/pnas.191361798.
24. Bridges RG, Sohn S-Y, Wright J, Leppard KN, Hearing P. 2016. The adenovirus E4-ORF3 protein stimulates SUMOylation of general transcription factor TFI-I to direct proteasomal degradation. mBio 7:e02184. https://doi.org/10.1093/microbiol/mob02184.15.
25. Vink EL, Yondola MA, Wu K, Hearing P. 2012. Adenovirus E4-ORF3-dependent relocalization of TIF-1γ and TIF-1γ relies on access to the coiled-coil motif. Virol 422:317–325. https://doi.org/10.1016/j.virol.2011.01.033.
26. Yondola MA, Hearing P. 2007. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol 81:4264–4271. https://doi.org/10.1128/JVI.02629-06.
27. Bridges RG, Sohn S-Y, Wright J, Leppard KN, Hearing P. 2016. The adenovirus E4-ORF3 protein stimulates SUMOylation of general transcription factor TFI-I to direct proteasomal degradation. mBio 7:e02184. https://doi.org/10.1093/microbiol/mob02184.15.
repressive activity on TGFβ signaling. J Cell Sci 126:3713–3723. https://doi.org/10.1242/jcs.126748.

29. Patsalo V, Yondola MA, Luan B, Shoshani I, Kisker C, Green DF, Raleigh DP, Hearing P. 2012. Biophysical and functional analyses suggest that adenovirus E4-ORF3 protein requires higher-order multimerization to function against promyelocytic leukemia protein nuclear bodies. J Biol Chem 287:22573–22583. https://doi.org/10.1074/jbc.M112.344234.

30. Ou HD, Kwiatkowski W, Deerinck TJ, Noske A, Blain KY, Land HS, Soria C, Powen CJ, May AP, Shu X, Tsien RY, Fitzpatrick JA, Long JA, Ellisman MH, Choe S, O'Shea CC. 2012. A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors. Cell 151:304–319. https://doi.org/10.1016/j.cell.2012.08.035.

31. Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK. 2007. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J 26:2797–2807. https://doi.org/10.1038/sj.emboj.7601711.

32. Mascle XH, Lussier-Price M, Cappadocia L, Estephan P, Raiola L, Omichinski JG, Aubry M. 2013. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation. J Biol Chem 288:36312–36327. https://doi.org/10.1074/jbc.M113.486845.

33. Capili AD, Lima CD. 2007. Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction. J Mol Biol 369:608–618. https://doi.org/10.1016/j.jmb.2007.04.006.

34. Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse A, Waddell MB, Bjornstø MA, Schulman BA. 2007. Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway. J Mol Biol 369:619–630. https://doi.org/10.1016/j.jmb.2007.04.007.

35. Nevels M, Tauber B, Kremmer E, Spruss T, Wolf H, Dobner T. 1999. Transforming potential of the adenovirus type 5 E4orf3 protein. J Virol 73:1591–1600.

36. Wilson VG. 2012. Sumoylation at the host-pathogen interface. Biomolecules 2:203–227. https://doi.org/10.3390/biom2020203.

37. Chang PC, Izumiya Y, Wu CY, Fitzgerald LD, Campbell M, Ellison TJ, Lam KS, Luciw PA, Kung HJ. 2010. Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem 285:5266–5273. https://doi.org/10.1074/jbc.M109.098098.

38. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. 2010. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J Virol 84:12210–12225. https://doi.org/10.1128/JVI.01442-10.

39. Tatham MH, Rodriguez MS, Xirolimatas DP, Hay RT. 2009. Detection of protein SUMOylation in vivo. Nat Protoc 4:1363–1371. https://doi.org/10.1038/nprot.2009.128.

40. Huang MM, Hearing P. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J Virol 63:2603–2615.

41. Evans JD, Hearing P. 2003. Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J Virol 77:5295–5304. https://doi.org/10.1128/JVI.77.9.5295-5304.2003.

42. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. 2006. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80:9687–9696. https://doi.org/10.1128/JVI.00738-06.

43. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 36:W465–W469. https://doi.org/10.1093/nar/gkn180.